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Abstract
Background: RSD921, the R,R enantiomer of the kappa (k) agonist PD117,302, lacks 
significant activity on opioid receptors.
Methods: The pharmacological and toxicological actions were studied with reference to 
cardiovascular, cardiac, antiarrhythmic, toxic and local anaesthetic activity.
Results: In rats, dogs and baboons, RSD921 dose-dependently reduced blood pressure and heart 
rate. In a manner consistent with sodium channel blockade it prolonged the PR and QRS intervals 
of the ECG. Furthermore, in rats and NHP, RSD921 increased the threshold currents for induction 
of extra-systoles and ventricular fibrillation (VFt), and prolonged effective refractory period 
(ERP). In rats, RSD921 was protective against arrhythmias induced by electrical stimulation and 
coronary artery occlusion. Application of RSD921 to voltage-clamped rat cardiac myocytes 
blocked sodium currents. RSD921 also blocked transient (ito) and sustained (IKsus) outward 
potassium currents, albeit with reduced potency relative to sodium current blockade. Sodium 
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channel blockade due to RSD921 in myocytes and isolated hearts was enhanced under ischaemic 
conditions (low pH and high extracellular potassium concentration). When tested on the cardiac, 
neuronal and skeletal muscle forms of sodium channels expressed in Xenopus laevis oocytes, 
RSD921 produced equipotent tonic block of sodium currents, enhanced channel block at reduced 
pH (6.4) and marked use-dependent block of the cardiac isoform. RSD921 had limited but 
quantifiable effects in subacute toxicology studies in rats and dogs. Pharmacokinetic analyses were 
performed in baboons. Plasma concentrations producing cardiac actions in vivo after intravenous 
administration of RSD921 were similar to the concentrations effective in the in vitro assays 
utilized.
Conclusions: RSD921 primarily blocks sodium currents, and possesses antiarrhythmic and local 
anaesthetic activity.
Keywords
RSD921; Sodium and potassium blocker; Antiarrhythmic; Toxicology; Electrophysiology; 
Pharmacokinetics; Myocyte; Langendorff; Neuromuscular; Local anesthetic
1. Introduction
Opioid receptors have been implicated in the genesis of arrhythmias due to myocardial 
ischemia [1–4], and a variety of experiments involving the use of both agonist and 
antagonist opiates have been used to support such claims [3–10]. However, one complication 
in the use of such drugs is that many also have ancillary pharmacological actions unrelated 
to opioid receptors. Thus, many opioid agonists and antagonists have antiarrhythmic actions 
which relate to actions on cardiac ion channels, particularly sodium channels [7,11–13], 
rather than actions on opioid receptors. We have found this to be the case for racemic kappa 
(k) opioid receptor agonists, and their respective optical enantiomers which lack potency on 
opioid receptors. Kappa agonism in this series of compounds resides predominantly in the 
S,S (−) enantiomers [14] whereas sodium current blockade and antiarrhythmic activity 
occurs in both S,S and R,R enantiomers [7]. In a previous study [7] we used enantiomeric 
pairs to establish that the antiarrhythmic actions were independent of κ receptor agonism. A 
systematic study of such enantiomers discovered that RSD921 (also known as PD123,497), 
the R,R (+) enantiomer of the racemic κ agonist, ( ± )PD117,302, originally developed by 
Clark et al. [15] was most potent in this regard.
Preliminary experiments suggested that RSD921 had a pharmacological profile similar to 
that of lidocaine, and that the profile was of potential therapeutic value as a local anaesthetic 
and/or antiarrhythmic drug. We employed pharmacological and toxicological studies to fully 
describe its actions both in vivo and in vitro in a variety of species. Our results demonstrate 
that RSD921 is a novel, potent sodium channel blocker with antiarrhythmic and local 
anaesthetic actions.
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2. Methods
2.1. In vitro studies with RSD921
2.1.1. Binding studies—RSD921 was tested for binding to sodium channels and opioid 
receptors. In the opioid binding studies, RSD921 was compared to its racemate, RSD920 
(( ± ) PD117,302).
2.1.2. Opioid receptor binding—The binding of RSD921 to mu (m), k and delta (d) 
opioid receptors and neuronal sodium channels was evaluated (Eurofins Pharma Discovery 
Services, Bothell, WA, USA) according to established radioligand binding study protocols. 
In order to study specific opioid binding, selective ligands were used. These were 
[3H]U-69,593 (3 nM) for k receptors, [3H](D-Ala2, N-methyl-Phe4, Gly-ol5)-enkephalin 
(DAMGO) (2 nM) for m receptors, [3H]D-Pen3, D-Pen5 enkephalin (DPDPE) (2 nM) for d 
receptors and [3H] Batrachotoxinin (BTX, 5 nM) for sodium channels (site 2).
Membrane aliquots were incubated in duplicate (to a total assay volume of 1 mL) with either 
[3H] DAMGO (0.5 nM) or [3H] U-69593 (0.5 nM) and increasing concentrations of 
RSD921 or RSD920. Non-specific binding was determined in the presence of morphine (10 
mM) or unlabeled U-69,593 for m and k receptors respectively. Veratridine (100 μM) was 
used for sodium channels. Incubations were performed at 25 °C for 60 min after which the 
reaction was terminated by filtration through glass fiber filter strips (Whatman GF/B). 
Approximately 24 h later the reactivity bound to the filters was quantified with liquid 
scintillation spectrometry performed at room temperature (25 °C). Data was analysed by 
linear regression analysis and expressed as IC50.
2.1.3. Studies in isolated tissue preparations
2.1.3.1. Langendorff isolated rat hearts.: Rat hearts (n = 6) were perfused on a modified 
Langendorff apparatus [7,12] at an aortic root pressure of 100 mmHg with piperazine-N,N’-
bis(ethanesulfonic acid) (PIPES) buffer at 35 °C oxygenated with 100% O2. A non-
compliant saline-filled balloon was used to produce an end-diastolic left-ventricular pressure 
of 10 mmHg. The peak left ventricular systolic pressure was recorded as well as the 
maximal rate of intraventricular pressure development (+dP/dtmax) and relaxation (−dP/
dtmax). The in vitro ECG was recorded using silver-ball wick electrodes placed on the left 
atrium and left ventricle.
Two buffer solutions were used in the isolated heart studies. The first, designated ‘normal’ 
buffer (pH = 7.4), was composed of the following (mM): NaCl 121, KCl 3.4, MgSO4 1.2, 
PIPES 13.9, Glucose 11.1, CaCl2 2.5. This allowed for examination of drug effects in a well 
standardized in vitro milieu. A second buffer, designated ‘ischemia-like’ because of the low 
pH (pH = 6.4) and high K + concentration, was composed of the following (mM): NaCl 115, 
KCl 10.1, MgSO4 1.2, PIPES 14.8, Glucose 11.1, and CaCl2 2.5. Use of these two solutions 
allowed for the actions of RSD921 to be determined in normal physiological milieu or in 
one which mimicked several of the conditions of myocardial ischemia.
Concentration-response curves for RSD921 were constructed in both buffers, and the 
concentrations required to elicit a 25% change from control measures (C25%) for the PR and 
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QRS intervals were estimated. An ‘ischemia-like to normal’ ratio (I:N) was calculated to 
provide an index for drug potency under ischemia-like versus normal conditions.
2.1.4. Isolated neuromuscular preparations—Rat phrenic nerve/diaphragm and 
hypogastric nerve/vas deferens neuromuscular preparations were prepared according to 
established methods [16,17]. Briefly, tissues were isolated with the corresponding nerve 
attached and suspended in tissue baths with resting tensions of 2 g (diaphragm) and 1 g (vas 
deferens). The tissues stabilized for 30 min prior to compound exposure. Control drugs 
included tetrodotoxin (TTX), naloxone and noradrenaline which were added to the bath and 
left in for 3 min. TTX (0.1 nM) immediately followed by noradrenaline (20μM) was given at 
both the beginning and the end of the vas deferens experiment, while for the diaphragm, 
TTX (1 nM) was given at the end of the experiment. All isolated preparations were bathed in 
Krebs-Henseleit solution (pH = 7.4) and aerated with carbogen (5% CO2, 95% O2). The 
composition (mM) of the Krebs-Henseleit solution was: NaCl, 118; KCl, 4.74; CaCl2•2H20, 
2.5; KH2PO4, 0.93; NaHCO3, 25; D-Glucose, 10; MgSO4•7H20, 1.2. Nerve stimulation was 
delivered at twice the threshold current (it) by silver bipolar electrodes placed on the phrenic 
and hypogastric nerves above the level of the bathing solution. Stimulation frequency was 20 
Hz for the hypogastric and 0.2 Hz for the phrenic nerve. The vas deferens was challenged 
every 2 min with a concentration of noradrenaline eliciting a sub-maximal response. The 
effect of RSD921 on nerve-induced contractions was determined by cumulative additions at 
3 min intervals until contractions could no longer be obtained. The EC50 values for 
inhibition of contraction were calculated for individual concentration-response curves.
2.1.5. Ion channel electrophysiology studies in isolated rat myocytes—Single 
cardiac myocytes were prepared by enzymatic digestion of isolated adult male rat hearts 
[12,18]. Isolated cells were settled onto a glass slide coated with poly-l-lysine and contained 
in a chamber with a bath solution flow rate of 1 mL/min. The bath solution (24 °C, pH = 
7.4) was composed of the following (mM): NaCl 130, KCl 5.4, MgCl2 1.0, CaCl2 2.0, 
CoCl2 5.0, CsCl 5.0, tetraethylsulphonic acid 10.0, NaOH 5.0, glucose 10.0 at a pH of 7.4. 
Evoked currents were recorded by conventional whole-cell patch clamp techniques. The 
composition of the electrode solution (mM) was: CsF 50.0, NaF 70.0, K-EGTA 20, CaCl2 
2.0, tetraethylsulphonic acid 10.0, ATP-Na2 5.0, ATP-Mg 5.0 at a pH of 7.4. While 
recording potassium currents, 50 μM TTX was added to the bath solution to block sodium 
channels. Microelectrode resistance was in the 5–10 MW range when containing solution, 
and cells were clamped using an Axopatch 200 A amplifier (Axon In-struments, Foster City, 
CA). Currents were filtered at 5 kHz, digitized at 10 kHz and stored in a microcomputer. 
Recordings were only done if at least 90% series resistance compensation could be achieved. 
Sodium currents were elicited every 3 s by a voltage step to 0 mV from a holding potential 
of −150 mV. The concentration-dependent effects of RSD921 (100 and 300μM) were 
examined on the transient outward (Ito) and sustained outward plateau (IKsus) potassium 
currents evoked by depolarisation to +50 mV from a pre-pulse potential of −150 mV for a 
duration of 300 ms. RSD921 was added either externally to the bathing solution or internally 
via addition to the electrode solution.
Walker et al. Page 4
Biomed Pharmacother. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2.1.6. Ion channel electrophysiology studies in Xenopus laevis oocytes—
Electrophysiological studies were performed using heart (rNav1.5), brain (rNav1.2) and 
skeletal muscle (rNav1.4) wild-type isoforms of the sodium channel obtained from rat tissue 
[19]. Plasmid DNA containing the full-length sodium channel coding region for each 
isoform was linearized and the linearized DNA (1.0 mg) was used for in vitro transcription. 
Stage V oocytes were obtained from adult female Xenopus laevis frogs, defolliculated with 
collagenase, and injected with in vitro transcribed RNA (50 nL). Forty-eight hours later, 
currents (1–4 mA) were evoked to examine the effects of RSD921.
Electrophysiological recording involved use of the two-electrode voltage clamp technique. 
Oocytes were clamped at a holding potential of −100 mV for rNav1.2 and rNav1.4, and at 
−120 mV for rNav1.5, and currents were evoked by 20 ms depolarization to −10 mV. 
Capacitative transient and leak currents were corrected by a P/4 protocol. Data was obtained 
and analysed using pCLAMP and filtered online. Non-linear curve-fitting was performed 
using SigmaPlot™ (Systat Software, Inc., San Jose, CA) and the Hill equation, y = Xn /(An
+Xn), where y is fractional response, X is concentration, A is the EC50, and n is the Hill 
coefficient [19]. All currents were allowed to recover from slow channel inactivation for at 
least 10 min prior to the conduct of any electrophysiological studies. Studies were conducted 
with RSD921 at pH 7.4 to obtain EC50 values. At a concentration of 30 μM, RSD921 block 
of sodium channel isoforms was also examined at pH 6.4 to determine whether there is an 
effect of pH on channel block. Frequency-dependent properties of RSD921 were examined 
on each sodium channel isoform using a 30-pulse stimulation protocol [19]. Cells were 
depolarized from a holding potential of −100 mV (−120 mV for rNav1.5) to −10 mV at a 
rate of 1 and 30 Hz. The effect of RSD921 on the sodium channels was examined by bath 
application [19] in a manner similar to that of lidocaine [20].
2.2. In vivo studies with RSD921
2.2.1. General in vivo methods—Male (CD-1) albino mice (18–25 g), and male 
Sprague-Dawley rats (200–350 g) (Charles River Laboratories, Montreal, Quebec) were 
used for all experiments that were conducted at the University of British Columbia (U.B.C). 
Male mongrel dogs weighing (25–30 kg) were obtained from the Animal Care Facilities at 
the University of Ottawa, Canada. Baboons (Papio annubis) of both sexes were kept in open-
range cages at the Animal Housing Facility at the National University of Singapore. Fifteen 
beagle dogs, 9 males (10–12 kg), and 6 females (8– 10 kg), were obtained from the 
Shanghai Medical University Breeding Unit at the Shanghai Medical University, China for 
experiments conducted at that University.
All experiments conducted at U.B.C. (mice, rats, humans) were performed according the 
guidelines outlined by the Animal Care Committee of the University of British Columbia 
and Research and those involving humans adhered to the principles of the Declaration of 
Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human 
Subjects, revised Nov 13, 2001. Informed consent was received from both volunteers and 
UBC IRB approval was waived. Those studies conducted in Singapore (baboons) were 
performed according to guidelines established by the National University of Singapore 
Animal Care Committee. Similarly, experiments conducted in Australia (rat ventricular 
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myocytes) were performed according to Animal Health & Welfare Regulations of the 
Australian National University. Studies approved by the University of Ottawa were 
performed there according to the guidelines of the Canadian Council on Animal Care. 
Studies in China were conducted according to approved University Animal Care Committee 
procedures. The study design and animal ethics conformed with ARRIVE [21] and more 
recent guidance on experimental design and analysis [22].
2.2.2. Cardiovascular studies in rats—Rats (n = 5) were anaesthetized with 
pentobarbital (60 mg/kg, i.p.) and artificially ventilated [23]. Body temperature was 
maintained at 36 ± 1 °C with a heating lamp. The left carotid artery and right jugular vein 
were cannulated for blood pressure measurements and administration of drugs respectively. 
Needle ECG electrodes were introduced with a lead II configuration. ECG variables 
measured included heart rate (HR), PR, QRS, QT intervals, as well as the ECG measure, 
RSh, introduced by Penz et al. [24].
2.2.3. Electrophysiological studies in rats, baboons and dogs
2.2.3.1. Electrical stimulation in rats.: Anaesthetized rats (n = 5) were prepared as 
described above and the left ventricle was stimulated using two Teflon™-coated silver wire 
electrodes inserted transthoracically [25]. Square wave stimulation was used to determine 
the threshold current for capture of the heart (it-mA), effective refractory period (ERP-ms), 
threshold current for the induction of VF (VFt) and maximum following frequency (MFF-
Hz) according to Walker and Beatch [26].
2.2.3.2. Electrical stimulation in baboons.: Male (18–28 kg) and female (10–15 kg) 
baboons were sedated with ketamine (10 mg/kg i.m.). Each animal was intubated and 
maintained with halothane (0.5–1.5 %) in humidified 100% oxygen and breathed 
spontaneously. The femoral vein and artery were cannulated percutaneously for the 
administration of saline or RSD921 and BP measurements, respectively. The external jugular 
vein was cannulated for introduction of a (Ag/AgCl2) monophasic action potential (MAP) 
dual pacing and recording electrode (7.0 French, EP Technologies, Sunnyvale, CA) [27]. 
The ECG was recorded from a lead II configuration. Blood pressure, right ventricular MAP 
and ECG were recorded and analysed off-line using customized pre-amplifiers and 
GlobalLab™ data acquisition software [27].
Prior to administration of RSD921 the threshold current (it), threshold duration for capture 
(tt), MFF (at twice it and tt), and right ventricular ERP (S1S2; train of 8–10 beats, 300 and 
500 ms cycle lengths) were determined. In addition, it was determined over a range of 
durations such that current amplitude (it) versus duration (tt) curves could be plotted as an 
index of sodium channel availability. Determinations were repeated so as to obtain three 
consistent estimates.
Once stable pre-drug recordings were obtained, RSD921 (0.2–6.4 μmole/kg), given as a 
slow bolus dose, was cumulatively administered at 30 min intervals. ECG and other 
variables were measured continuously so that time-effect curves could be plotted. 
Electrophysiological variables were determined 3 min (it, tt and it vs tt) and at 10 min (ERP) 
after drug administration (n = 4).
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2.2.3.3. Conduction velocity studies in dogs.: A four-lead 2 × 2 cm bipolar recording 
electrode array plaque was sewn onto the right ventricular epicardium of open-chest mongrel 
dogs (n = 3) anaesthetized with chloralose (10 mg/kg/hr) and fentanyl (75 mg/kg) [27]. The 
electrodes were used to determine conduction velocities for responses evoked by stimulation 
at 500 ms via an electrode that was placed at a corner of the electrode array plaque.
2.2.3.4. Ischemia-induced arrhythmias in rats.: Antiarrhythmic efficacy of RSD921 
against occlusion-induced arrhythmia was examined in rats subjected to occlusion of a 
branch of the left anterior descending (LAD) coronary artery [6,28,29]. Animals were given 
30 min. to recover after surgery prior to administration of RSD921. Five min after 
commencement of drug administration, ischemia was induced by ligature occlusion of the 
LAD artery. Arrhythmias were summarized as an arrhythmia score (AS) which was 
calculated using the occurrence after occlusion of premature ventricular contractions (PVC), 
the number and duration of ventricular tachycardia (VT), and ventricular fibrillation (VF) 
episodes according to the Lambeth Conventions [30,31] and as defined by Curtis and Walker 
[32]. Fifteen min after LAD occlusion, the animals were euthanized and the occluded zone 
(OZ or zone-at-risk) was determined [33] by perfusing the heart in Langendorff fashion with 
a Krebs-Henseleit solution containing 1 mg/ml Indocyanin (cardiac green) dye. Rats were 
excluded if their occluded zone (ischaemic ventricular mass) lay outside the range of 25–
45% of the total ventricular mass. Two blood samples (0.5 ml each) were taken from the 
carotid artery for measurement of serum K+ concentration prior to drug administration, and 
15 min after occlusion. Potassium-selective electrodes (Accumet model 25 pH/ion meter, 
Fisher Scientific, Pittsburgh, PA) were used to determine serum K+ concentration.
2.2.3.5. Local anaesthetic studies in mice, guinea pigs and humans.: The local 
anaesthetic actions of RSD921 were assessed in mice, guinea pigs and humans for regional 
and dermal block.
2.2.3.6. Regional block anesthesia
2.2.3.6.1. Tail anesthesia in mice.: Sixty mice were divided into 3 groups, each of which 
received one of RSD921, lidocaine or saline in two 20 ml injections close to the base of the 
tail. Concentrations of RSD921 solutions used were 0.05%, 0.1%, 0.2%, 0.4%, and 1.0%, 
and lidocaine concentrations were 0.1%, 0.2%, 0.5%, and 1.0%. Two min after injection, the 
pin prick test was conducted proximally and distally to the injection site with a positive 
response being a tail flick.
2.2.3.6.2. Sciatic nerve block in mice.: Sciatic nerve blockade by RSD921 was 
investigated using previously described methods [34]. To determine the onset time of 
regional anesthesia by RSD921 compared to lidocaine, thirty-six CD-1 female mice were 
given saline, RSD921 or lidocaine at 0.063% (1.6 mM), 0.125% (3.2 mM), and 0.25% (6.4 
mM). These compounds (50 mL) were injected into the popliteal space, in the area 
surrounding the sciatic nerve. Any mouse that could not use the injected hindlimb to walk on 
top and on an inverted wire mesh was considered to have a positive response. The onset time 
was recorded as the time from injection when a mouse displayed a positive response.
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To determine time to recovery from regional anesthesia, forty-eight CD-1 female mice were 
injected in the popliteal space with RSD921 or lidocaine at 0.063% (1.6 mM), 0.125% (3.2 
mM), 0.25% (6.4 mM), 0.5% (12.8 mM) and 1.0% (25.6 mM) concentrations in a 
randomized blinded design. Recovery was defined as the ability to walk normally on top and 
on the inverted wire mesh for at least 15 s, and was evaluated every 5 min from the time of 
injection until full recovery was attained. Neuromuscular blockade was also evaluated and 
defined as the ability to walk normally on top of the wire mesh screen but not hang on to the 
inverted screen.
2.2.3.7. Intradermal anesthesia
2.2.3.7.1. Guinea pigs.: Intradermal toxicity and local anaesthetic actions of RSD921 were 
studied in guinea pigs. The backs of male guinea pigs (300–400 g) were shaved 24 h prior to 
the start of the experiment. Concentrations of 0.063%, 0.125%, 0.25%, 0.5%, and 1% 
RSD921 and lidocaine were injected subcutaneously in the dorsal area using 27 G needles. 
Guinea pigs received either the RSD921 concentration range (n = 5) or the lidocaine 
concentration range (n = 3) for a total of 6 injections per animal. To assess local anesthesia, 
a 10 g weighted needle was used to prick each bleb site 10 times at 1, 2, and 5 min, and 
every 5 min thereafter for a total of 60 min. Local anesthesia was determined by calculating 
the ratio of the number of positive responses (no flinch) to the number of negative responses 
(flinch).
2.2.3.7.2. Humans.: Local anaesthetic actions of RSD921 were compared with those of 
lidocaine by means of intradermal injections in two male volunteers. Sites of injection were 
marked on the ventral surfaces of the forearms. Various concentrations of RSD921 or 
lidocaine dissolved in distilled water were injected in a volume of 0.2 ml in a random and 
masked manner. The state of anesthesia at each injection site was assessed at 5, 10, 15, 20, 
25, and 30 min after injection by pricking the area 10 times with a pin. In some experiments 
RSD921 and lidocaine solutions also contained naloxone.
2.3. Toxicology of RSD921
2.3.1. Acute toxicity in mice—Various doses (1.0–12.5 mg/kg) of RSD921 were 
administered via the tail vein. Mortality was recorded 24 h after administration, and the 
maximum tolerable dose, defined as the dose that resulted in mortality in 50% of the mice 
was determined along with its 95% confidence limits.
2.3.2. Sub-acute toxicity in rats and dogs—In a 14-day study, rats were injected 
with RSD921 (10 mmole/kg, 0.1 ml/kg, i.v.) in the tail vein, while control rats received 
corresponding volumes of saline. Injections were made with a 25G-Long Butterfly needle 
twice daily, at 8.30 a.m. and at 4.30 p.m. The rats were observed for physiological and 
behavioral changes at 1 min and 30 min subsequent to each injection. Blood samples (1 mL) 
were extracted from all animals prior to drug or saline exposure, mid-treatment (day 7) and 
post-treatment (day 14). On days 7 and 14, the samples were taken before the first injection. 
Blood samples were kept for blood cell count, peripheral (differential) smears and 
hematological analysis. After 15 days the animals were euthanized with carbon dioxide, and 
post mortem examinations conducted. Organs (consisting of a standard panel including 
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brain, heart, lung, liver, kidneys, and stomach) were removed, preserved in 10% neutral 
buffered formalin, and subjected to histopathological examination.
Toxicity tests in beagle dogs were preceded by a 7-day conditioning period, during which 
daily measurements of cardiovascular parameters (see below) were made. For a total of 14 
days, dogs were given RSD921 (either 1 or 5 mmol/kg, i.v., BID) or appropriate volumes 
normal saline administered over 10 min. Observations were made according to a double 
blinded design during injection, at 5, 15, 30, and 60 min following injection, and included 
measurements of blood pressure, heart rate, ECG, gross behavior, and mortality. Body 
weight was measured daily. At day 7 and day 14 blood and urine samples were taken for 
hematological and biochemical analyses. Following 14 days of treatment, 60% of the dogs 
(2 males, 1 female per group) were euthanized, and subjected to gross pathological and 
histological examinations. The remaining 40% of the dogs (1 male, 1 female per group) 
recovered for 7 days to observe any potential delayed toxicological events and recovery 
characteristics. At day 21 blood and urine samples were drawn and the animals were 
sacrificed.
2.3.3. Pharmacokinetic studies in rats and baboons—A single tail vein injection 
of RSD921 (8 μmol/kg, i.v.) was given and the resulting tissue (brain, heart, liver, and 
skeletal muscle) and whole blood concentrations determined in rats. The results of this 
pharmacokinetic study were described by Walker et al. [35]. Brain, heart, liver and skeletal 
muscle (right hind leg) samples were removed and rinsed in cold saline. Briefly, samples 
were homogenized and stored frozen at −20 °C until analysis. Preparation for analysis 
involved organic extraction with methyl-t-butyl ether, back-extraction into sulfuric acid, and 
organic re-extraction. Purified samples were analyzed using reversed-phase high-
performance liquid chromatography (HPLC) coupled with UV detection (215 nm). Tissue 
sample drug recovery from the extraction procedure ranged from 77 to 90% with a minimum 
detection limit of 80 ng/ml and maximum limit of 200 ng/ml per gram of tissue or mL of 
blood analyzed [35]. This is the first quantitative method described for measurement of an 
arylacetamide of this type in biological matrices [35].
Blood samples were collected from two male baboons (weighing 23 and 28 kg respectively) 
under halothane anesthesia at 5, 15, and 30 min after cumulative i.v. bolus doses of 0.2, 0.4, 
0.8, 1.6, and 3.2 μmol/kg RSD921. Blood samples were collected from the neck area, mixed 
with heparin (1000 IU/mL), and diluted with saline. Samples were quantitatively analysed 
by high performance liquid chromatography (HPLC).
2.4. Statistical analysis
Unless otherwise indicated values are expressed as the mean ± standard deviation (s.d.) for n 
experiments. Statistical analyses were usually performed using an NCSS statistical package 
(NCSS LLC, Kaysville, Utah), and accepting an a-level of 0.05 as indicating statistical 
significance. A general linear model analysis of variance (ANOVA) followed by Duncan’s 
test for critical differences between means were used. In arrhythmia studies some data was 
log10 transformed in order to normalize data for parametric statistical testing. Mainland’s 
contingency tables [36] were used to determine significance between incidences of events. 
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In isolated heart studies, drug effects were expressed as percentage changes from control 
conditions. Generally, non-linear dose or concentration response curves were fitted by least 
squares approximation to the logic function of the form y = Xn (An+Xn)−1 using GraphPad 
Prism (Win version 5.04, La Jolla, CA, USA).
2.5. Drugs
RSD921 ((+)-trans-N-methyl-N-[2-(1-pyrrolidinyl)cyclo-hexyl] benzo[b]thiophene-4-
acetamide) and RSD920 (( ± )-N-methyl-N-[2-(1-pyrrolidinyl)cyclo-
hexyl]benzo[b]thiophene-4-acetamide) were synthesized in the laboratories of Rhythm 
Search Developments Ltd, a wholly owned subsidiary of Nortran Pharmaceuticals Inc. 
Naloxone hydrochloride dihydrate ((5α)-4,5-Epoxy-3,14-dihydroxy-17-(2-propen-1-
yl)morphinan-6-one) (PubChem CID:5464092), lidocaine hydrochloride (2-(diethylamino)-
N-(2,6-dimethylphenyl)acetamide) (PubChem CID 6314), noradrenaline tartarate (PubChem 
CID 439260) and piperazine-N,N’-bis(ethanesulfonic acid) (PIPES) buffer (PubChem CID 
10193124) were purchased from Sigma Chemical Co. (St. Louis, MO) and tetrodotoxin 
(TTX) (PubChem CID 11174599) was purchased from Tocris Bioscience (Bristol, UK). All 
drugs were dissolved distilled water or in normal saline (0.9% NaCl) prior to i.v. injection or 
dissolution in the external bath solution of in vitro study preparations.
3. Results
3.1. In vitro actions of RSD921
RSD921 is a substituted arylbenzacetamide with IUPAC designation (1R,2R)-(+)-N-methyl-
N-[2-(1-pyrrolidinyl)cyclohexyl]benzo[b]thiophene-4-acetamide monochloride. The 
molecular weight for the hydrated hydrochloride salt is 406 g/mol and it has a melting point 
of 147 °C with a lipid partition coefficient (log P) of 1.59.
3.2. Binding studies
3.2.1. Opioid receptor binding—Whereas RSD921 was equipotent on m receptors and 
sodium channels (at site 2, the BTX site), the concentrations required to displace the k-
specific ligand were 10–20 fold lower than those required to displace m receptor and sodium 
channel radioligands. IC50 values were found to be 0.4 ± 0.05 mM, 7.6 ± 1.2 mM, and 6.8 
± 0.9 mM for the k receptor, m receptor, and sodium channel, respectively. The Ki values 
were 0.2 ± 0.02 mM for the k receptor, 0.9 ± 0.1 mM for the m receptor, and 6.1 ± 0.8 mM 
for the sodium channel. RSD921 had negligible effects on d receptors (data not shown).
3.2.2. A comparison to racemic RSD920—RSD920, the racemate containing the S,S 
enantiomer, possessed higher affinity for both m (80-fold) and k (1000-fold) receptors. The 
IC50 of RSD920 against m receptors in the same radioligand binding assay was 0.01 mM 
while that of RSD921 was 7.6 mM. The IC50 of RSD920 against k receptors in the same 
binding assay was 0.0004 mM while that of RSD921 was 0.4 mM. The fact that LD50 values 
derived from mice for both RSD920 and RSD921 were almost identical (10 mmol/kg for 
RSD920 and 23 mmol/kg for RSD921) strongly suggested that mortality was unrelated to 
opioid activity.
Walker et al. Page 10
Biomed Pharmacother. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
3.2.3. Studies in isolated tissue preparations
3.2.3.1. Isolated rat hearts.: In isolated rat hearts perfused with ‘normal’ buffer solution 
(pH 7.4 and 3.4 mM K+) RSD921 prolonged the PR and QRS intervals of the in vitro ECG 
(Fig. 1A) and depressed heart rate but also increased left-ventricular peak systolic pressure 
(LVP) (Fig. 1B). When isolated hearts were perfused with an ‘ischemia-like’ buffer solution 
(pH 6.4 and 10.1 mM K+), the potency of RSD921 was increased. An ischemia-like/normal 
ratio (which acts as an indicator of ischemic tissue efficacy) was calculated based on the 
concentrations of RSD921 required to produce an increase in the PR interval by 25% (C25) 
in both buffer solutions (Fig. 2). The ischemia-like/normal ratio was 0.33 for the normal 
buffer C25 (3μM). This ratio ranged between 0.2–0.6 over the concentration range 0.03–30 
μM.
3.2.4. Isolated neuromuscular preparations—In the rat diaphragm/phrenic nerve 
preparation, RSD921 produced a concentration-dependent inhibition of contraction (EC50 = 
100 μM). Contractions were also inhibited concentration-dependently by RSD921 (EC50 = 
15 μM) in the vas deferens/hypogastric nerve preparation. The two resulting curves showed 
remarkably different shapes. The curve for the diaphragm/phrenic nerve data had a very 
steep slope, while that for the vas deferens/hypogastric nerve data was much less steep (Fig. 
3). In both preparations, the inhibition of nerve-or noradrenaline-induced contraction by 
RSD921 was not reversed by naloxone whereas it was abolished by TTX (EC50 ~0.001 μM).
3.3. Electrophysiological studies with RSD921
3.3.1. Actions in isolated rat myocytes—The bath application of RSD921 (1–30 
μM) to isolated cardiac myocytes subject to whole-cell voltage clamp resulted in a 
concentration-dependent inhibition of evoked sodium currents (Fig. 4A). The IC50 was 3.8 
± 0.5μM (n = 3 cells) with a slope (Hill coefficient, nH) of 1.3 ± 0.2 using the best fits of the 
equation INa = 1/[1+(KA/[A]). Naloxone (5μM) had no influence on the sodium current 
blocking activity of RSD921 (Fig. 4B).
Fig. 5 shows the effects of whole-cell recording with RSD921 (130μM) added to the pipette 
solution. Unlike the rapid blocking actions seen when the drug was bath perfused, very little 
block of current occurred when currents were evoked beginning at 4 min after patch rupture. 
After an additional 4 min of intracellular drug application the sodium current was only 
reduced by 18% (note that without drug in the pipette the current amplitude was 26 ± 7 nA, 
n = 3). In the presence of intracellularly applied RSD921 (130μM), bath applied RSD921 
(130μM), produced an immediate, marked and readily-reversible inhibition of the sodium 
current (Fig. 5).
Under acid bath conditions (pH6.4) there was a limited increase (~15% greater block at 10 
μM) in RSD921 sodium current blocking potency (data not shown). At concentrations ~25-
fold higher than that required to block sodium currents, RSD921 also blocked potassium 
currents. RSD921 (100 and 300 μM) produced block of the peak component of Ito as well as 
IKsus as shown in the cell in Fig. 6.
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3.3.2. Actions in Xenopus laevis oocytes expressing sodium current—
RSD921 produced a concentration-dependent blockade of sodium current evoked in oocytes 
at physiological pH 7.4 [19]. When the data were fit using a Hill equation for a 
concentration range of 1–1000 mM, the following EC50 values were obtained: 47 ± 3 mM 
for rNa v1.5, 37 ± 4 mM for rNav1.2 and 35 ± 3μM for rNav1.4. Under similar study 
conditions, when peak sodium current was determined and fit using the Hill equation, the 
EC50 value for lidocaine was 563 ± 22 μM [20]. Thus, RSD921 has a 12–fold greater 
potency for cardiac sodium channel blockade than lidocaine at physiological pH values in 
the oocyte expression system.
The effect of RSD921 (30 μM) on channel block was also examined at pH6.4 on all sodium 
channel isoforms (n = 4–10 oocytes). At pH 7.4 RSD921 reduced sodium current to 60 ± 5% 
for rNav1.5, 48 ± 6% for rNav1.2 and 51 ± 2% for rNav1.4 while at pH6.4 channel block 
was 50 ± 1% for rNav1.5, 47 ± 7% for rNav1.2 and 34 ± 2% for rNav1.4. Thus, for both the 
cardiac and skeletal muscle isoforms a reduction in pH enhanced channel block.
RD921 produced a marked use-dependent block of cardiac currents. At a frequency of 30 
Hz, RSD921 (100 mM) blocked 81 ± 4% of the evoked rNav1.5 current. In contrast, the 
same concentration of RSD921 produced a 40 ± 5% block of rNav1.4 currents and only a 24 
± 3% of rNav1.2 currents. RSD921 produced no significant use-dependent actions at 1 Hz 
[19].
3.4. In vivo results with RSD921
3.4.1. Cardiovascular actions in rats
3.4.1.1. Effects of RSD921 on blood pressure, heart rate and ECG in rats.: RSD921 
given intravenously as a slow bolus produced dose-related decreases in blood pressure and 
heart rate in anaesthetized rats. The hypotensive and bradycardic responses resulting from 
intravenous doses of RSD921 are shown in Table 1. These doses also had effects on the ECG 
which was most marked in terms of an increase in the PR interval. At the peak dose (8 
μmol/kg) these ECG effects were most pronounced. At this dose the PR interval was 
prolonged from a control saline value of 60 ± 2 ms to 112 ± 3 ms while the QRS interval 
was prolonged from 30 ± 1 ms to 39 ± 2 ms. The amplitude of RSh was increased from 0.40 
± 0.06 to 0.88 ± 0.03 mV. Similarly, this dose prolonged the QT interval from 48 ± 2 ms to 
59 ± 3 ms (Table 1).
3.4.2. Cardiovascular and electrophysiological actions in rats, baboons and 
dogs
3.4.2.1. Effects on electrical stimulation in rats.: Slow bolus doses of RSD921 produced 
dose-dependent increases in current thresholds for induction of single extrasystoles (it) and 
ventricular fibrillation (VFt) as well as an increase in the effective refractory period (ERP) of 
the rat myocardium (Fig. 7). The increased threshold currents suggest a concentration-
dependent antiarrhythmic action against electrically-induced arrhythmia in the rat.
3.4.2.2. Effects on electrical stimulation in baboons.: In anaesthetized baboons (n = 4) 
the hemodynamic (Fig. 8A) and ECG effects (Fig. 8B) of RSD921 given i.v. were similar to 
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those seen in rats and occurred over approximately the same dose range. Notably lower 
predrug blood pressures were encountered in baboons anaesthetized with halothane (83 ± 5 
mmHg) as compared to rats anaesthetized with pentobarbital (152 ± 6 mmHg). This initial 
low blood pressure appeared to potentiate the hypotensive effect of RSD921 in these 
animals. RSD921 produced dose-dependent increases in both the PR and QT intervals to 
maximum values of 69 ± 9% and 79 ± 5%, respectively at a dose of 6.4 mg/kg (Fig. 8B). 
Ventricular excitability curves (current thresholds: amplitude (i) versus duration (t)) in 
baboons were recorded 5 min after doses 0.2–3.2 μmol/kg. Fig. 9 shows that RSD921 
produced a dose-dependent shift in the ‘i vs. t’ curve to the right. The effects of RSD921 on 
the baboon cardiac AP were studied at two dose levels: 0.25 mmol/kg/min infused for 10 
min, and 0.5 mmol/kg/min infused for 15 min. As shown in Fig. 10, RSD921 prolonged AP 
duration (APD) at 25, 50 and 75% repolarization with the highest dose producing the 
greatest effect (n = 4).
3.4.2.3. Conduction velocity effects in dogs.: In open-chest dogs (n = 3), administration 
of RSD921 at doses of 1, 2 and 4 μmol/kg given every 5 min produced a dose-related 
decrease in conduction velocity in the left ventricular epicardium (Fig. 11). The decrease 
was accompanied by hemodynamic ECG changes similar to those seen in rats and baboons.
3.4.2.4. Actions on ischemia-induced arrhythmia in rats.: The antiarrhythmic efficacy 
of RSD921 was tested in rats subjected to coronary artery occlusion and RSD921 reduced in 
the incidence of PVC, VT, and VF (Table 2). At the 1.0 μmol/kg i.v. dose, VF incidence was 
reduced to 0% compared to 80% in control animals. Animals at the highest dose 
administered did not survive the observation period due to insufficient cardiac output 
resulting from coronary occlusion. RSD921 reduced arrhythmia incidence without changing 
the occluded zone (ischaemic zone) size or serum K+ concentration.
Arrhythmia protection by RSD921 occurred at doses which were significantly lower than 
those which produced marked changes in ECG and BP measurements. The efficacy and 
potency of RSD921 in protecting against ischemia-induced arrhythmias was comparable to 
its efficacy and potency against electrically-induced arrhythmias (VFt). RSD921 was also 
equipotent in producing hypotension in ischemia and electrical models of arrhythmia 
induction.
3.4.3. Local anaesthetic actions in mice and rats
3.4.3.1. Regional analgesia
3.4.3.1.1. Tail anesthesia in mice.: RSD921 produced concentration-dependent local 
anesthesia in mice. Its efficacy and potency were comparable to that of lidocaine. At 0.1, 
0.2, 0.4, and 1% concentrations RSD921 produced local anesthesia in 33%, 100%, 60%, and 
100% of the mice tested, respectively. Lidocaine at 0.1, 0.2, 0.5, and 1% concentrations 
produced local anesthesia in 17%, 80%, 17%, and 100% of the mice tested, respectively.
3.4.3.1.2. Sciatic nerve block in mice.: There was no sign of neuromuscular blockade by 
either RSD921 or lidocaine. At the same concentrations, RSD921 and lidocaine were not 
statistically different from each other in times to onset of anesthesia. The onset time of 
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RSD921 (0.063%) was 70 ± 24 s while that of lidocaine at the same concentration was 42 
± 3 s. The onset time for RSD921 (0.125%) was 62 ± 13 s, while that for lidocaine (0.125%) 
was 37 ± 24 s. RSD921 (0.25%) produced anesthesia at 25 ± 13 s, compared to the 37 ± 13 s 
taken by the same concentration of lidocaine. Recovery from anesthesia was concentration-
dependent for both drugs, although the recovery time from RSD921 was much longer than 
that from lidocaine at the same concentrations. Table 3 shows the mean recovery times for 
RSD921 and lidocaine. It is interesting to note that whereas at least 83% of RSD921-treated 
mice were anaesthetized at all concentrations of RSD921 used, lidocaine produced 
anesthesia in only 50% of the animals at lower concentrations (0.063% and 0.125%); this 
suggests that RSD921 is at least 2-fold more potent than lidocaine in producing anesthesia
3.4.3.1.3. Intradermal anesthesia in guinea pigs.: The time to maximum measured 
response was approximately 1 min post injection and occurred at higher doses of lidocaine 
(0.5% and 1%) and RSD921 (0.5% and 1%). Times to peak response for lidocaine and 
RSD921 at lower concentrations (0.063%, 0.125% and 0.25%) were also similar and fell 
within 3–5 min post injection. RSD921 produced a longer duration of local anesthesia 
(approximately 2-fold), with concentrations of 0.063% and 0.5% lasting up to 55 min post-
injection, as compared to 35 min duration for the same concentrations of lidocaine. 
Furthermore, RSD921 (1%) produced local anesthesia for a duration of 80–85 min, whereas 
recovery occurred at 40 min with the same concentration of lidocaine. The threshold 
concentrations for local anesthesia could not be determined at the range of RSD921 and 
lidocaine concentrations used in this study.
3.4.3.1.4. Intradermal analgesia in humans.: Intradermal injection of RSD921 produced 
a wheal and analgesia in both subjects. RSD921 was 4 times as potent as lidocaine in 
producing analgesia, since an 800 mM concentration of RSD921 produced analgesia 
comparable to 3200 mM lidocaine. In addition, the duration of anesthesia produced by 
RSD921 was longer than that produced by lidocaine. In experiments where RSD921 was 
administered with naloxone, all mixtures of the two drugs produced analgesia.
3.5. Toxicological effects of RSD921
3.5.1. Acute toxicity in mice and rats—Two modalities of death were observed after 
bolus dose injection of RSD921 in mice. Lower doses appeared to cause death from 
respiratory failure within 15 min of injection. Higher doses appeared to cause cardiac arrest 
within 20 s of injection. The maximum tolerable doses for such respiratory deaths were 
calculated to be 19 μmol/kg (95% confidence limits of 15–24 μmol/kg). The corresponding 
values for cardiac deaths were 87.3 μmol/kg (95% confidence limits of 48–160 μmol/kg). 
The approximate maximum tolerable dose for anaesthetized rats was 16 μmol/kg. In a 
limited number of studies, the maximum tolerated dose in conscious rats was 10 μmol/kg. 
This dose produced early preconvulsive signs (e.g., hypothermia, straub tail, hyperactivity 
and tremor). Animals given twice this dose died immediately from cardiac arrest as deduced 
from ECG evidence. Conscious dogs given 10 μmol/kg over a period of 10 min also showed 
signs of a pre-convulsive state (e.g., glazed visual response, aphasia, hyperactivity and 
tremor). Where comparisons were made, doses causing lethality in anaesthetised animals 
were also lethal in conscious animals.
Walker et al. Page 14
Biomed Pharmacother. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
3.5.2. Sub-acute toxicity in rats and dogs—Approximately one min after injection, 
rats receiving RSD921 (10 mmol/kg) were hypoactive compared to the controls. 
Hypoactivity included decreased locomotor activity, grooming, rearing, climbing, and 
increased stupor. RSD921 induced episodes of ataxia evidenced by an abnormal gait, and 
markedly flattened postures in the first min after injection. Ataxia was not observed in any 
animal 30 min after dosing was complete. No significant differences in food consumption, 
water intake, body weight and temperature between the RSD921-treated and control rats 
were observed throughout the study (data not shown). In terms of gross pathology, kidney 
discoloration (pale-white mottled patches) were apparent on the surface of 2 RSD921 treated 
rats and in one saline-treated rat. No microscopic changes were observed. Histopathological, 
biochemical and hematological analysis showed no significant differences between saline-
treated controls and RSD921-treated animals (data not shown).
Sub-acute toxicity studies in dogs showed that RSD921 (5 mmol/kg) induced reversible 
convulsions, muscular spasms, tremor, salivation, and asthenia, symptoms which appeared 
during infusion, and which lasted about 10 min. Following infusion of RSD921 (5 mmol/
kg), heart rate and blood pressure decreased for 5–10 min before slowly recovering. Apart 
from the prolonged R-R interval (heart rate), no changes in the ECG were observed. At 1 
mmol/kg, the above responses were not observed, although the animals were quiet, early 
after injection. Histopathological examination of animals sacrificed after 14 days of drug 
administration (5 mmol/kg) revealed minor changes in the liver and kidneys; however, these 
changes were reversed in the 1-week recovery period in animals sacrificed at day 21. No 
such changes were observed in controls and animals that received 1 mmol/kg dose of 
RSD921.
3.5.3. Pharmacokinetic studies in rats and baboons—In a pharmacokinetic study, 
rats were given a single bolus dose of RSD921 (8.0 μmol/kg, i.v.) and the tissue and blood 
levels were quantified [33]. Analysis of the concentration-versus-time response curves (drug 
levels per gram tissue or mL of blood) showed that disposition of RSD921 was greatest in 
the heart (29 μg/g tissue) followed by blood (7.5 μg/mL), brain (6.5 μg/g tissue), skeletal 
muscle (2.6 μg/g tissue) and liver (0.5 μg/g tissue). Tissue recovery of RSD921 was highest 
in the heart at 85 ± 2.1% and lowest in the brain at 77 ± 0.7%. It was found that the t½ value 
for the a phase (rapid phase of elimination) was 30 s and for the ß-phase (slow phase of 
elimination) was approximately 90 min. Determination of these tissue levels of the drug 
showed that elimination from the rat heart was followed by sequestration in the brain and 
liver [35].
Plasma concentrations of RSD921 were determined in baboons following cumulative bolus 
i.v. doses (0.2, 0.4, 0.8, 1.6 and 3.2 μmol/kg) and are shown in Fig. 12. Each cumulative 
dose of RSD921 produced a proportional increase in plasma concentration of RSD921 with 
the largest increase occurring after the 3.2 μmol/kg dose. The elimination half-life (t½) for 
RSD921 was determined to be 12 min. Such trends in responses suggested that RSD921 
redistributes within tissues and that this, and not metabolism, may be responsible for 
termination of the cardiac effects subsequent to bolus dose administration. Studies 
performed using rat liver microsomal preparations showed that there was no significant 
metabolism of RSD921 over a 32 min period (data not shown).
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4. Discussion
The purpose of this series of studies was to determine the pharmacological profile of 
RSD921, a novel sodium and potassium current blocking drug, with reference to 
antiarrhythmic and local an-aesthetic actions. Where appropriate, the pharmacology of 
RSD921 was compared to that of lidocaine using data obtained in this study or data available 
in the literature. Based upon the profile of its cardiac actions in vitro and in vivo we suggest 
that sodium current blockade with RSD921 occurs from binding to an extracellular site on 
the channel pore protein. Blockade is rapid, reversible, and concentration (or dose) de-
pendent. The drug is more selective for blockade of sodium currents than for at least two 
repolarizing cardiac potassium currents.
The evidence for sodium and potassium blocking actions is consistent from studies 
conducted investigating effects at the ion channel level up to changes in physiological 
responses in various animal species. Thus, RSD921 blocks the cardiac, neuronal and skeletal 
muscle forms of the sodium channel heterologously expressed in oocytes and blocks both 
sodium and potassium channels in myocytes. The actions of RSD921 on isolated hearts are 
consistent with findings in myocytes. In rats the effects of the drug on the ECG are 
consistent with findings in isolated hearts. Furthermore, RSD921 influences responses to 
electrical stimulation in rats in a manner which is also consistent with blockade of sodium 
and potassium currents. An increase in threshold current and duration for induction of 
electrical arrhythmias is to be expected to occur with sodium channel blockers while 
prolongation of the effective refractory period can occur with potassium channel blockers as 
well as sodium channel blockers, particularly those which are frequency dependent in their 
actions.
The electrophysiological findings in rat tissue are recapitulated in other species. Thus, in 
baboons RSD921 prolongs both the QRS and QT intervals and has a pattern of effects on 
electrical stimulation which is the same as that seen in rats. Furthermore, in dogs RSD921 
prolongs conduction velocity in a manner expected of a sodium channel blocker [37–39].
The full scope of ion channel blockade produced by RSD921 was not determined in the 
current set of studies. However, the available evidence suggests that with respect to sodium 
channel blockade this might occur via actions at an extracellular binding site. However, 
neuronal and skeletal isoforms of the channel are also blocked by RSD921.
The major action of RSD921 on evoked sodium currents in isolated rat myocytes was to 
reduce the maximum sodium channel conductance; however, the drug only caused a minor 
hyperpolarizing shift in the kinetics of channel inactivation without changing activation (data 
not shown). Pugsley & Goldin [19] found that while RSD921 was a potent sodium channel 
blocker in all wild-type sodium channel isoforms it also produced open channel blockade of 
the IFMQ3 mutant channel. This mutant results in the loss of fast channel inactivation 
properties of the channel and is a useful tool to probe drug effects on the state dependence of 
block. In addition, a slow recovery kinetic assessment from open channel block of the 
IFMQ3 channel with RSD921 suggests that the interaction between RSD921 and the sodium 
channel occurs in the open state and can account for tonic as well as use-dependent block 
Walker et al. Page 16
Biomed Pharmacother. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
[19]. Together, these studies suggest that the putative site of drug interaction for this 
arylacetamide may be in the outer vestibule region of the pore since intracellular application 
of the drug did not result in significant channel block until it was bath applied which 
supports the theory of drug-mediated open channel block at an extracellular binding site.
Two binding sites have been suggested for the sodium channel: an intracellular binding site 
[37–39], and an extracellular one [40–42]. The high efficacy of RSD921 in blocking sodium 
currents when applied from the bathing fluid favors an extracellular site of action on the 
sodium channel. The fast onset of action and rapid reversal of drug effect also provides 
support for the likelihood of an external site of blockade. The perfusion cannulas used 
ensured minimal delay to the time of exposure [18], thus the results clearly showed that, 
independent of drug concentration, half-maximal block by RSD921 occurred within 5–10 s 
after application. Similarly, the perfusion apparatus used in the isolated heart study allowed 
for very rapid (< 2 s) changes in perfusate to be made, therefore it was possible to observe 
the rapid onset and offset of blockade [43]. As was the case with isolated myocytes, 
blockade of sodium current occurred within 10 s of exposure in the isolated heart 
preparations, and the drug had the same wash-out rate in both preparations.
Additional data to support an external site of action comes from the enhanced action of the 
drug under ischaemic conditions both in myocytes, oocytes and isolated hearts. This is in 
agreement with earlier observations made by other laboratories that the external sodium 
channel site is pH-dependent [40,44–47]. It should be noted that an external site of action, as 
well as an increase in activity at low pH, have both been demonstrated for ( ± ) PD117302, 
the active enantiomer of (+)PD123,497 [7]. Nevertheless, the extracellular site of action on 
the sodium channel ascribed to RSD921 is in marked contrast to standard Class I 
antiarrhythmics which act “internally” as open channel blockers [48,49].
The lack of effect of naloxone on the RSD921-induced blockade of sodium currents in the 
myocytes indicates that this effect of RSD921 was independent of opioid receptor activation. 
This is in full agreement with the lack of kappa opioid activity observed for RSD921 
[49,50], and its low affinity for m opioid receptors [51,52].
RSD921 was found to inhibit nerve-induced contractions of the vas deferens and diaphragm 
without influencing contractions due to noradrenaline (vas deferens) and KCl (both 
preparations). Given that contractions induced by noradrenaline and KCl were not affected, 
and with the understanding that blockade of neuromuscular transmission can occur at a 
number of different loci, it would be reasonable to assume that such actions were related to 
nerve blockade, presumably neuronal sodium channel blockade. The concentrations required 
to inhibit contractions in this preparation were considerably higher (see below) than those 
required to block sodium currents in the myocytes or decrease ventricular pressure in the 
isolated heart, and this may indicate greater efficacy in blocking myocardial sodium 
channels than neuronal sodium channels. The ability of RSD921 to cause mortality both in 
mice and rats by way of cardiac arrest supports our view of direct depression of myocardial 
excitability by this compound.
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The outward potassium currents examined in myocytes in this study have two components: a 
rapid transient phase, Ito, and a delayed, sustained phase, IKsus [12,53,54], of which the 
transient outward is the major repolarizing current in the rat heart [54–56]. At 100 and 
300μM, concentrations that produced complete blockade of cardiac sodium currents, 
RSD921 attenuated the potassium currents during the transient phase, and reduced the 
magnitude of the delayed potassium current. Generally, the concentrations required to inhibit 
potassium currents were at least 10 times greater than those which inhibited the sodium 
current. With this respect the electrophysiological spectrum of RSD921 is similar to that 
characterized for Class Ia antiarrhythmic drugs.
The high selectivity for, and fast onset of, sodium current blockade observed in the isolated 
single ventricular cells was indirectly substantiated by experiments on isolated hearts. In 
isolated hearts RSD921 produced both PR and QRS prolongation. It is generally accepted 
that widening of the QRS interval reflects a depression of the phase 0 sodium currents and a 
reduction in ventricular conduction velocity [56]. PR interval prolongation in the hearts of 
small animals is primarily derived from sodium channel blockade (unlike larger mammals) 
and depression of conduction in atrial tissue [57]. Although it has been observed that L-type 
calcium channel blockers prolong the PR interval in the rat by way of depressing inward A–
V nodal calcium current [58], this mechanism is unlikely to play a role in the case of 
RSD921 as it occurs at high doses of these drugs associated with non-selective channel 
block. In the isolated hearts there is no clearly definable T wave and therefore QT 
measurements reflecting potassium current blockade [59] were not made; however, the effect 
of RSD921 on this variable could be established in the intact rat where it prolonged PR, 
QRS and QT intervals. The marked PR interval prolongation, as compared to either QRS 
width or the QT measure, reflects the greater blocking action of RSD921 on sodium 
channels. As expected from its effects in prolonging PR and QRS intervals, RSD921 also 
affected RSh which is taken as a measure of sodium channel blockade in the rat [24]. While 
this measure seems to be valid for use in the rat, its significance may be questionable when it 
comes to humans [60]. In full agreement with the results obtained in rats, electrical 
stimulation studies both in rats and Baboons provide further evidence for sodium channel 
blockade by RSD921. In both animal species RSD921 shifted the position of ventricular 
excitability (i versus t) curves and reduced cardiac contractility. Slowed conduction velocity 
observed in dogs is entirely consistent with blockade of voltage and time dependent sodium 
channels. Thus, RSD921 appeared to exhibit a preferential sodium channel blockade in three 
mammalian species.
The hypotensive and bradycardic effects of RSD921 in animals (rats, dogs, baboons) are 
consistent with those observed with Class 1a anti-arrhythmic agents. Although kappa 
agonists depress contractions in various vascular tissues such as the rat tail artery [61] and 
porcine coronary circumflex artery [62] it is unlikely that RSD921 acts through this 
mechanism due to its lack of opioid activity. A more probable postulate is that the 
hemodynamic effects of RSD921 may derive from both peripheral vasodilatation and 
myocardial depression resulting from sodium and potassium blockade. It is of interest to 
note that a bradycardic response in rats was observed in the absence of a decrease in blood 
pressure and this can easily be explained by pertaining a direct myocardial depressant effect.
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The argument favoring ion channel blockade as an underlying mechanism for RSD921 is 
further supported by other observations made in our laboratory and by others. For example, 
U-50,488H (the first κ-opioid receptor agonist developed) was shown to produce 
hemodynamic effects and possess antiarrhythmic actions in a manner consistent with sodium 
and potassium current blockade [6,12]. In a study further analyzing the actions of 
PD129,290, a potent kappa agonist and its R,R enantiomer (PD129,289) with only 1/1000th 
kappa agonist potency, it was clearly demonstrated that the antiarrhythmic, ECG and electro-
physiological effects were related to channel blocking actions rather than to actions on 
opioid receptors [7]). The results with RSD921, an R,R enantiomer of the racemic kappa 
agonist PD117,302 are consistent with the above findings which have been reviewed by 
Pugsley et al. [63,64].
In order to determine the relationship between effects seen in vitro and those observed in 
vivo a pharmacokinetic analysis was performed. Doses of RSD921 associated with i.v. 
effects in intact animals were similar to those concentrations producing in vitro isolated 
heart and ventricular cell effects, but considerably lower than those inhibiting neuronally-
induced smooth or skeletal muscle contraction.
The sodium channel blocking activity of RSD921 was found to establish marked 
antiarrhythmic activity both against ischemia-induced as well as electrically-induced 
arrhythmias. Based on the lack of effect on serum K+ concentration or OZ size it is unlikely 
that RSD921 exerts its antiarrhythmic activity by modifying these parameters. The increases 
in it and VFt produced by RSD921 were achieved at doses higher than those required to 
protect against occlusion-induced arrhythmias. This observation leads to the conclusion that 
the antiarrhythmic actions of RSD921 are more selective for occlusion-induced arrhythmias 
as compared to electrically-induced arrhythmias.
Regarding the sub-acute, chronic toxicity profile for RSD921, our studies in rats showed that 
RSD921 is rather non-toxic at relatively high doses (in the range of half LD50 values) under 
the conditions stated. Apart from the transient motor and autonomic disturbances noted at 
high doses in beagle dogs, no permanent histological changes were discovered in the brain 
during evaluation. The reversible toxicological effects observed in the liver and kidney at 
high doses and the absence of any obvious histopathological changes at low doses in dogs 
would suggest that RSD921 is relatively devoid of specific end-organ toxicities.
With respect to the assessment of local anaesthetic activity in mice, guinea pig and human 
studies, the potency and efficacy of RSD921 suggest it could be a good substitute for 
lidocaine.
A rapid pharmacokinetic distribution of RSD921 in rat blood and tissues following the 
administration of a single bolus dose was reported by Walker et al. (33). Similarly, based on 
data obtained from blood samples taken after dosing in baboons, the elimination half-life 
(t½) was determined to be 12 min. Overall, rapid tissue uptake and subsequent elimination 
primarily occurs in the heart but is followed by sequestration in the brain and liver 
suggesting that redistribution, and not metabolism, may be responsible for termination of 
cardiac effects following injection of the drug.
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5. Conclusions
In animals RSD921 dose-dependently reduced blood pressure and heart rate. RSD921 
applied externally to patch-clamped myocytes blocked sodium currents independent of 
opioid activity. At higher concentrations RSD921 also produced potassium channel 
blockade. Sodium channel blockade exerted by RSD921 was expressed as prolongation of 
PR and QRS intervals of the ECG both in isolated preparations and in animals. Similarly, 
RSD921 increased the thresholds for electrical induction of extra-systoles and ventricular 
fibrillation and prolonged effective refractory periods in rats. RSD921-induced sodium 
channel blockade was enhanced under ischaemic conditions both in myocytes, oocytes and 
isolated hearts. The cardiac sodium channel isoform was found to be more sensitive to the 
blocking effect of RSD921 than the neuronal isoform. The toxicological effects of RSD921 
appear to be related to excessive cardiac sodium current blockade.
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Fig. 1. 
Concentration-response effects of RSD921 on the PR and QRS intervals of the ECG (A) and 
left ventricular pressure (LVP) and heart rate (HR) (B) in rat Langendorff hearts. Data shows 
the percent change from control after 5 min exposure to different concentrations of drug in a 
normal (pH7.4, K+ 3.4 mM) PIPES buffer at 35 °C. Values are mean ± s.d. for n = 6. Using a 
nonlinear curve fit for the data, the correlation coefficient for the PR interval, HR and LVP 
was p < 0.01 and the QRS interval was p < 0.001.
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Fig. 2. 
Concentration-response effects of RSD921 on the PR interval of the ECG in rat Langendorff 
hearts. Data shows the percent change from control after 5 min exposure to different 
concentrations of drug in a normal (pH7.4; K+ 3.4 mM) or ischemic (pH6.4; K+ 10.1 mM) 
PIPES buffer at 35 °C. Values are mean ± s.d. for n = 6. Using a nonlinear curve fit for the 
data, the correlation coefficient for the PR interval was p < 0.001.
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Fig. 3. 
Concentration-response effects of RSD921 on the rat phrenic nerve/diaphragm and 
hypogastric nerve/vas deferens neuromuscular preparations. Stimulation (at a frequency of 
20 Hz for the hypogastric and 0.2 Hz for the phrenic nerve) was delivered using electrodes 
placed on the each nerve above the level of the Krebs-Henseleit bathing solution. The effect 
of RSD921 on nerve-induced contractions was determined by cumulative additions at 3 min 
intervals. EC50 values were calculated for each preparation. Using a nonlinear curve fit for 
the data, the correlation coefficient for the rat phrenic nerve/diaphragm curve was p < 0.05 
and for the hypogastric nerve/vas deferens was p < 0.001.
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Fig. 4. 
The effects of RSD921 on sodium currents in isolated rat myocytes. Panel A shows sodium 
current traces evoked by a voltage-step from a pre-pulse potential of −150 mV to a potential 
of 0 mV. The voltage step was delivered at 3 s intervals and RSD921 was added to the bath 
solution at the concentrations indicated. The recontrol (washout) current amplitude is 
comparable to the control. Panel B shows the concentration-response curve for blockade of 
the sodium current by RSD921 (n = 3). The half-maximal sodium current block (IC50) from 
this data, using the best fits of the equation INa = 1/[1+(KA/[A]) was 3.8 ± 0.5μM with a 
slope (Hill coefficient, nH) of 1.3 ± 0.2. In the presence of naloxone (5μM) the IC50 was 
unchanged (open symbols). The curves described by the solid lines were best fit by the Hill 
equation as described in the Methods.
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Fig. 5. 
The ion channel blocking effects of RSD921 were examined to determine if block occurs 
with application of drug outside or inside the myocyte. Whole cell recording was achieved 
with RSD921 (130μM) inside the patch pipette. Sodium currents were evoked by a voltage 
step to 0 mV from a pre-pulse potential of −150 mV for 4 min after patch rupture of the 
myocyte. These voltage steps were given at 6 s intervals and currents generated were plotted 
as a function of time. RSD921 (130μM) was added to the bath solution as indicated by the 
bar).
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Fig. 6. 
The effects of RSD921 (100 and 300μM) were examined on depolarization-induced 
transient outward (Ito) and sustained outward plateau (IKsus) potassium currents. Currents 
were elicited by depolarisation to +50 mV from a pre-pulse potential of −150 mV for 300 
msec. RSD921 was perfused into the bath in the presence of 50μM tetrodotoxin (TTX) and 
currents subsequently evoked.
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Fig. 7. 
Effects of RSD921 on electrical stimulation variables and induction of arrhythmias in 
anaesthetized rats. RSD921 dose-dependently increased the threshold current for induction 
of extrasystoles (it) and ventricular fibrillation (VFt) and prolonged the effective refractory 
period (ERP). Values (mean ± s.d. for n = 5 animals) were measured after completion of 
each dose. *Indicates a significant difference from pre-treatment at p < 0.05. Using a 
nonlinear curve fit for the data, the correlation coefficient for VFt was p < 0.01.
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Fig. 8. 
Effects of RSD921 on the blood pressure (panel A) (BP) and ECG (panel B) measures (PR 
and QT intervals) in male and female baboons (n = 4). Values (mean ± s.d. for n = 4 
animals) shown were measured 2 min. after completion of each bolus dose. *Indicates a 
significant difference from pre-treatment at p < 0.05. Using a nonlinear curve fit for the data, 
the correlation coefficient for the BP and QT interval was p < 0.01 and the PR interval was p 
< 0.001. Pre-treatment mean control PR interval was 126 ± 3msec and QT interval was 262 
± 18msec.
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Fig. 9. 
Effect of RSD921 (0.2–6.4 μmole/kg), given as a bolus dose, on monophasic action potential 
threshold current (it) versus duration (tt) in the right ventricle of anaesthetized baboons. Data 
shown is for electrophysiological variables determined 3 min (it, tt and it vs tt) after dose 
administration. Using a nonlinear curve fit for the data, the correlation coefficient for all it vs 
tt curves was p < 0.05. For the sake of clarity, error bars are omitted in the figure.
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Fig. 10. 
Effect of RSD921 (0.2–6.4 μmole/kg), given as a bolus dose, on the cardiac APD in the right 
ventricle of anaesthetized baboons. Data shown is for changes in APD (25, 50 and 75%) 
determined 10 min after dose administration. *Indicates a significant difference from pre-
treatment (0 μmol/kg) at p < 0.05.
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Fig. 11. 
Dose response effects of RSD921 on conduction velocity (CV) in anaesthetized dogs (n = 
3). RSD921 (1, 2 and 4 μmol/kg) was given every 5 min producing a dose-related decrease 
in CV. Individual CV values are plotted for each dog.
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Fig. 12. 
Plasma concentrations associated with cumulative i.v. bolus doses (0.2–3.2 μmol/kg) of 
RSD921 in anaesthetized male baboons (n = 2). Individual plasma values are plotted for 
each baboon.
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Table 2
Antiarrhythmic profile of RSD921 in anaesthetized rats.
Dose (μmole/kg) PVC Log10 PVC VT VF Mortality AS
0 94 2.0 9/10 8/10 8/10 6.0 ± 0.7
0.1 62 1.8 7/7 5/7 3/7 4.6 ± 0.8
0.25 30.4 1.5 3/5 1/5 1/5 2.4 ± 1.3
0.5 123.2 2.1 3/6 0/6 0/6 1.7 ± 0.8
1 34.6 1.5 2/5 0/5 0/5 1.8 ± 1.0
2 20.0 1.3 3/11 0/11 10/11 ND
Ventricular tachycardia (VT), ventricular fibrillation (VF) and mortality are listed as a ratio of the total number of rats. Premature ventricular 
contraction (PVC) incidence is log10 normalized. Arrhythmia scores (AS) are listed as group mean ± s.d. ND = Not determined as all the animals 
dosed in this group upon occlusion had insufficient cardiac output to survive the 30 min observation period.
Biomed Pharmacother. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Walker et al. Page 38
Table 3
The duration of regional anesthesia produced by RSD921 in the sciatic nerve of mice.
Drug Concentrations (%) Lidocaine (min) RSD921 (min)
0.063 0.7 ± 0.3 4 ± 0.6
0.125 1.3 ± 0.6 13 ± 4
0.25 5 ± 0 40 ± 3
0.5 8 ± 1 52 ± 3
1.0 23 ± 3 81 ± 8
Time (min) refers to time to recovery from anesthesia. Values are expressed as mean ± s.d.
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